A molecular investigation into a patient’s unexplained thrombocytopenia has uncovered evidence that the interleukin-33 pathway may play a more direct role in platelet production and blood-cell regulation than previously recognized. The study, published in Genes & Immunity, examines two coding variants affecting IL-33 signaling: a rare, previously unreported change in the IL33 gene and a more common variant in IL1RL1, the gene encoding the IL-33 receptor ST2. Together, the findings connect structural changes in an immune-signaling pathway to altered receptor activity and raise new questions about how inflammatory networks influence hematopoiesis.
IL-33 is best known as an alarm signal released by damaged or stressed cells. Once outside the cell, it binds to ST2 on the surface of immune cells, including type 2 innate lymphoid cells, mast cells, eosinophils and several populations of T cells. ST2 does not signal alone. It forms a receptor complex with the interleukin-1 receptor accessory protein, IL-1RAcP, enabling the intracellular assembly of signaling proteins that activate pathways such as NF-κB and MAP kinases. These pathways can reshape gene expression, promote inflammation and influence tissue repair. Increasing evidence, however, suggests that IL-33 signaling also affects the bone marrow and the production or survival of blood components, including platelets.
The researchers focused on a patient carrying two missense variants. The first, IL33 c.385T>C, replaces tyrosine with histidine at position 129 of the IL-33 protein, producing the Y129H substitution. This variant was rare and novel, making its biological significance uncertain at the outset. The second alteration occurred in IL1RL1: c.1501_1502CA>AG, which changes glutamine to arginine at position 501 of ST2, known as Q501R. Unlike the IL-33 variant, Q501R is relatively common and has previously been associated with weaker IL-33 responses and a lower risk of asthma in genetic studies.
To determine how Y129H might affect the cytokine, the investigators used structural modeling of the IL-33/ST2/IL-1RAcP ternary complex. In this assembly, IL-33 must make precisely positioned contacts with ST2 and the accessory receptor. The modeling indicated that tyrosine 129 participates in a conserved hydrogen-bonding network that helps stabilize receptor engagement. Replacing tyrosine with histidine changes both the geometry and chemical properties of that contact. Tyrosine contains an aromatic ring and a hydroxyl group capable of forming stable interactions, whereas histidine contains a smaller imidazole ring whose charge and hydrogen-bonding behavior can vary with local conditions. The predicted result was a less stable interface between IL-33 and its receptor.
Laboratory experiments supported that structural prediction. The Y129H form of IL-33 showed markedly reduced binding affinity for the receptor complex and substantially diminished biological activity in functional assays. In practical terms, the altered cytokine was less capable of initiating the signaling response normally triggered by IL-33. The researchers therefore classified Y129H as a loss-of-function variant. This conclusion is significant because it moves the variant beyond a computational prediction: the amino-acid substitution was linked directly to impaired molecular binding and reduced cellular activity.
The second variant, ST2 Q501R, affects a very different part of the signaling system. Position 501 lies within the cytoplasmic Toll/interleukin-1 receptor, or TIR, domain of ST2. Unlike the extracellular region that recognizes IL-33, the TIR domain functions inside the cell and helps recruit adapter proteins after receptor activation. One of its most important partners is MyD88, an adapter that connects IL-1 family receptors to downstream kinases and transcription factors. Structural modeling suggested that replacing neutral glutamine with the positively charged amino acid arginine substantially perturbs a peripheral helix in the TIR domain.
That alteration could influence how ST2 interacts with MyD88 or with other components of the signaling machinery. The study does not establish that Q501R completely blocks adapter recruitment, but it offers a mechanistic explanation for earlier genetic observations linking the variant to reduced IL-33 signaling and protection against asthma. A relatively subtle change in the receptor’s intracellular architecture may tune the intensity, duration or cellular context of the inflammatory response rather than simply switching signaling on or off.
The simultaneous presence of weakened IL-33 activity and a potentially altered ST2 signaling domain is especially notable in a patient with thrombocytopenia, a condition characterized by an abnormally low platelet count. Platelets are produced by megakaryocytes in the bone marrow, and their production is influenced by cytokines, stress signals and interactions between hematopoietic cells and the marrow environment. IL-33 may participate in this network by influencing progenitor-cell behavior, inflammatory support cells or stress-responsive pathways that become important when blood-cell production is challenged. The study therefore raises the possibility that impaired IL-33/ST2 signaling contributed to the patient’s platelet phenotype.
The authors emphasize that the findings do not yet prove that either variant alone causes thrombocytopenia. The patient carries two changes in the same pathway, and the clinical observation comes from a single case. Other genetic, environmental or medical factors could also be involved. Nevertheless, the combination of structural predictions and functional testing provides a compelling framework for future research. Studies in larger patient cohorts, engineered cell systems and animal models will be needed to determine whether IL-33 and ST2 variants consistently influence platelet production or recovery after hematopoietic stress.
The broader message is that immune signaling pathways cannot always be confined to traditional categories such as inflammation or allergy. IL-33 and ST2 operate at the intersection of tissue damage, immune activation and blood-cell regulation. By revealing how one amino-acid substitution weakens cytokine-receptor binding and another reshapes an intracellular signaling domain, the study illustrates how human genetic variation can alter biology at atomic, cellular and clinical scales. These insights may eventually help explain otherwise unexplained blood-count abnormalities and identify patients whose platelet disorders are linked to defects in stress-responsive immune signaling.
Subject of Research: Structural and functional effects of coding variants in the IL-33/ST2 signaling pathway, with implications for thrombocytopenia, asthma susceptibility and platelet homeostasis.
Article Title: Structural and functional consequences of IL33 and IL1RL1 coding variants on IL-33/ST2 signaling.
Article References: Gelon, L., Roga, S., Nahoum, V. et al. “Structural and functional consequences of IL33 and IL1RL1 coding variants on IL-33/ST2 signaling.” Genes & Immunity (2026). https://doi.org/10.1038/s41435-026-00410-5
Image Credits: AI Generated
DOI: 10.1038/s41435-026-00410-5; published 04 August 2026
Keywords: IL-33, IL1RL1, ST2, thrombocytopenia, platelets, hematopoiesis, asthma, missense variants, protein structure, MyD88 signaling, cytokine receptors, immunogenetics
Tags: blood cell regulation by interleukin-33genetic influence on immune receptor functionIL-33 receptor ST2IL-33 signaling pathwayIL1RL1 gene variantsimmune pathway alterations in hematological disordersimmune signaling in hematopoiesisinflammatory regulation of blood cell productionNF-κB and MAP kinase activation in immune responsereceptor complexrole of IL-33 in tissue repairstructural impact of IL-33 mutationsthrombocytopenia and cytokine pathways
